PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS

Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more...

Full description

Saved in:
Bibliographic Details
Main Authors FLORJANCIC, ALAN S, GOSWAMI, RAJEEV, TONG, YUNSONG, SOUERS, ANDREW J, PENNING, THOMAS
Format Patent
LanguageEnglish
French
Published 02.10.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia). L'invention concerne un composé de Formule (Ia), où R1, R2 et R3 sont tels que définis dans la description, et des sels pharmaceutiquement acceptables de celui-ci. Les composés peuvent être utilisés en tant qu'agents dans le traitement de maladies, comprenant le cancer. L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs composés de Formule (Ia).
AbstractList Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia). L'invention concerne un composé de Formule (Ia), où R1, R2 et R3 sont tels que définis dans la description, et des sels pharmaceutiquement acceptables de celui-ci. Les composés peuvent être utilisés en tant qu'agents dans le traitement de maladies, comprenant le cancer. L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs composés de Formule (Ia).
Author PENNING, THOMAS
TONG, YUNSONG
GOSWAMI, RAJEEV
SOUERS, ANDREW J
FLORJANCIC, ALAN S
Author_xml – fullname: FLORJANCIC, ALAN S
– fullname: GOSWAMI, RAJEEV
– fullname: TONG, YUNSONG
– fullname: SOUERS, ANDREW J
– fullname: PENNING, THOMAS
BookMark eNrjYmDJy89L5WTQDIgMCvL38QdSnr6efi6efq4Kzi7elgrenn6Owa4Knn4enk6eIf5BwTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jA0MTQzMDAyMLR0Jg4VQDY-ydO
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate INHIBITEURS DE PYRROLOPYRIMIDINE CDK9 KINASE
ExternalDocumentID WO2014160028A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2014160028A13
IEDL.DBID EVB
IngestDate Fri Jul 19 15:30:43 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2014160028A13
Notes Application Number: WO2014US25670
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20141002&DB=EPODOC&CC=WO&NR=2014160028A1
ParticipantIDs epo_espacenet_WO2014160028A1
PublicationCentury 2000
PublicationDate 20141002
PublicationDateYYYYMMDD 2014-10-02
PublicationDate_xml – month: 10
  year: 2014
  text: 20141002
  day: 02
PublicationDecade 2010
PublicationYear 2014
RelatedCompanies ABBVIE INC
RelatedCompanies_xml – name: ABBVIE INC
Score 2.952404
Snippet Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20141002&DB=EPODOC&locale=&CC=WO&NR=2014160028A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKeqbTsXplIJS8KFYu7ZpH4asN1p1TemqzqfRrgkIMoer-Pc9jZ3uaU-5QW7w5eTLuQTgiui5wTi7VUpiqYrOVa4Utl0qGiFWaeeYF4HnR7EZPun3E2PSgveVL4yIE_otgiMiomaI90qc14v_RyxP2FYub4o3rPq4C7KBJzfsuDZaVDXZcwZ-Qj3qyq6LvE2O09-2WgdlDZErbeFFmtR48J-d2i9lsS5Ugn3YTrC_eXUALTbvwK67-nutAzujRuWN2QZ9y0O4Tl7TlD5STPDIib0o9iXXe7AlpODDsS9FcRg5UUbT8RFcBn7mhgqOOf1b4vSFrk-wfwxtJP_sBKQSZaxBOC-IruqEsdxSTV7YfZPxGe5u3oXepp5ONzefwV5dFMZpWg_a1ecXO0chWxUXYm9-AIR4e3I
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQWl4EOxdm3TPgxZv2jd-kFXdXsa7ZqAIHO4iv--17jpnvaUkINLcnB3-eUuF4BbouYaZfRBKokhSyqTmVSYZikphBilmWOfF54PI91_Vp_G2rgB7-u3MLxO6DcvjogaNUN9r7i9XvxfYjk8t3J5X7zh0Mejl_UccYWO66RFWREdq-cmsRPbom0jbhOj9JdWx6CMPmKlHTxkk1of3Berfpey2HQq3gHsJshvXh1Cg87b0LLXf6-1YS9chbyxu9K-5RHcJZM0jYcxNmhyIieIXMF2BqaAELw_coUg8gMryOJ0dAw3npvZvoRzTv-2OH2NNxfYPYEmgn96CkKJPlYjjBVElVVCaW7IOivMrk7ZDKWbn0FnG6fz7eRraPlZOJwOg2hwAfs1iSeqKR1oVp9f9BIdblVccTn9AHn8fmU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PYRROLOPYRIMINDINE+CDK9+KINASE+INHIBITORS&rft.inventor=FLORJANCIC%2C+ALAN+S&rft.inventor=GOSWAMI%2C+RAJEEV&rft.inventor=TONG%2C+YUNSONG&rft.inventor=SOUERS%2C+ANDREW+J&rft.inventor=PENNING%2C+THOMAS&rft.date=2014-10-02&rft.externalDBID=A1&rft.externalDocID=WO2014160028A1